These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33027788)

  • 1. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients.
    Abdel-Wahab R; Hassan MM; George B; Carmagnani Pestana R; Xiao L; Lacin S; Yalcin S; Shalaby AS; Al-Shamsi HO; Raghav K; Wolff RA; Yao JC; Girard L; Haque A; Duda DG; Dima S; Popescu I; Elghazaly HA; Vauthey JN; Aloia TA; Tzeng CW; Chun YS; Rashid A; Morris JS; Amin HM; Kaseb AO
    Oncology; 2020; 98(12):836-846. PubMed ID: 33027788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma.
    Kaseb AO; Xiao L; Hassan MM; Chae YK; Lee JS; Vauthey JN; Krishnan S; Cheung S; Hassabo HM; Aloia T; Conrad C; Curley SA; Vierling JM; Jalal P; Raghav K; Wallace M; Rashid A; Abbruzzese JL; Wolff RA; Morris JS
    J Natl Cancer Inst; 2014 May; 106(5):. PubMed ID: 24815863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort.
    Huber Y; Bierling F; Labenz C; Koch S; Schmidtmann I; Kloeckner R; Schotten S; Huber T; Lang H; Woerns MA; Galle PR; Weinmann A; Weinmann-Menke J
    BMC Cancer; 2018 Jul; 18(1):774. PubMed ID: 30064393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
    Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma.
    Abdel-Wahab R; Shehata S; Hassan MM; Xiao L; Lee JS; Cheung S; Essa HH; Hassabo HM; Shalaby AS; Mosad E; Raghav K; Rashid A; Wolff RA; Morris JS; Amin HM; Kaseb AO
    Oncotarget; 2015 Aug; 6(25):21193-207. PubMed ID: 26098859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.
    Kaseb AO; Morris JS; Hassan MM; Siddiqui AM; Lin E; Xiao L; Abdalla EK; Vauthey JN; Aloia TA; Krishnan S; Abbruzzese JL
    J Clin Oncol; 2011 Oct; 29(29):3892-9. PubMed ID: 21911725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.
    Kaseb AO; Abbruzzese JL; Vauthey JN; Aloia TA; Abdalla EK; Hassan MM; Lin E; Xiao L; El-Deeb AS; Rashid A; Morris JS
    Oncology; 2011; 80(5-6):373-81. PubMed ID: 21822028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of five models for end-stage liver disease in predicting the survival rate of patients with advanced hepatocellular carcinoma.
    Hong YF; Chen ZH; Ma XK; Li X; Wu DH; Chen J; Dong M; Wei L; Wang TT; Ruan DY; Lin ZX; Wen JY; Lin Q; Jia CC; Wu XY
    Tumour Biol; 2016 Apr; 37(4):5265-73. PubMed ID: 26561464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study.
    Cho EJ; Lee JH; Yoo JJ; Choi WM; Lee MJ; Cho Y; Lee DH; Lee YB; Kwon JH; Yu SJ; Lee JM; Suh KS; Kim K; Kim YJ; Yoon JH; Kim CY; Lee HS
    Clin Cancer Res; 2013 Aug; 19(15):4218-27. PubMed ID: 23757355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of HCC-MELD Score in Patients With Hepatocellular Carcinoma Undergoing Liver Transplantation.
    Guerrini GP; Pinelli D; Marini E; Corno V; Guizzetti M; Zambelli M; Aluffi A; Lincini L; Fagiuoli S; Lucianetti A; Colledan M
    Prog Transplant; 2018 Mar; 28(1):63-69. PubMed ID: 29251164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Insulin-Like Growth Factor-1 (IGF-1): a Novel Prognostic Factor for Early Recurrence of Hepatocellular Carcinoma (HCC).
    Yao Y; Mao W; Dong M; Yang D; Li W; Chen Y
    Clin Lab; 2017 Feb; 63(2):261-270. PubMed ID: 28182337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sequential changes of the model for end-stage liver disease score correlate with the severity of liver cirrhosis in patients with hepatocellular carcinoma undergoing locoregional therapy.
    Huo TI; Lee PC; Huang YH; Wu JC; Lin HC; Chiang JH; Lee SD
    J Clin Gastroenterol; 2006 Jul; 40(6):543-50. PubMed ID: 16825938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Liver Transplant-Related Survival Benefit in Patients With Versus Without Hepatocellular Carcinoma in the United States.
    Berry K; Ioannou GN
    Gastroenterology; 2015 Sep; 149(3):669-80; quiz e15-6. PubMed ID: 26021233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MELD-Na is an independent short- and long-term prognostic predictor for hepatocellular carcinoma: a prospective survey.
    Huo TI; Lin HC; Hsia CY; Huang YH; Wu JC; Chiang JH; Chiou YY; Lui WY; Lee PC; Lee SD
    Dig Liver Dis; 2008 Nov; 40(11):882-9. PubMed ID: 18339595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
    Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
    Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients.
    Tang JY; Ohri N; Kabarriti R; Aparo S; Chuy J; Goel S; Schwartz JM; Kinkhabwala M; Kaubisch A; Guha C
    Can J Gastroenterol Hepatol; 2018; 2018():5681979. PubMed ID: 30533403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of the model for end-stage liver disease (MELD) on liver transplantation in one center in Brazil.
    Freitas AC; Itikawa WM; Kurogi AS; Stadnik LG; Parolin MB; Coelho JC
    Arq Gastroenterol; 2010; 47(3):233-7. PubMed ID: 21140081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
    Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
    Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.